Editorial Type: Veterinary Practice Guidelines
 | 
Online Publication Date: 01 Sept 2017

2017 AAHA Canine Vaccination Guidelines*

DVM, MS, DACVIM, DACVPM (Hon),
DVM,
DVM, JD,
PhD, DACVM (Hon), and
DVM, DABVP
Article Category: Research Article
Page Range: 243 – 251
DOI: 10.5326/JAAHA-MS-6741
Save
Download PDF

Executive Summary

The American Animal Hospital Association (AAHA) is pleased to introduce this revision of the Canine Vaccination Guidelines published, for the first time, as an online educational resource for the veterinary medical profession. This format will allow for frequent online updates as necessary. The revised AAHA Canine Vaccination Guidelines offer important updates to the 2011 Guidelines. The content of the Guidelines has been significantly expanded to facilitate efforts by practicing veterinarians to meet patient and client needs in a complex infectious disease environment. The Guidelines are an authoritative source of evidence-based recommendations and expert opinion provided by the AAHA Canine Vaccination Guidelines Task Force. The Task Force includes individuals with extensive experience in primary care practice, academia, shelter medicine, public health, and veterinary law related to clinical practice.

While there is often consensus on which canine vaccines fall into core and noncore categories and when they should be administered, in practice, the vaccination protocol should always be individualized based on the patient’s risk factors, life stage, and lifestyle. For this reason, these Guidelines are not intended to represent a universal vaccination protocol applicable to all dogs. Instead, the Guidelines offer a range of recommendations that will aid practitioners in making rational decisions on vaccine selection for their individual patients.

The AAHA Canine Vaccination Guidelines offer important updates to previously published guidelines as well as new, relevant information that directly impacts the practicing veterinarian:

  • Updated, quick-reference tables summarizing vaccination recommendations for client-owned and shelter-housed dogs.

  • Internet links that provide ready access to regularly updated online sources of information that will supplement the Guidelines themselves, for example, state-by-state information on rabies vaccination law and regulations, and comprehensive information on vaccine storage and handling.

  • Algorithms outlining indications for antibody testing (serology) as well as recommended actions for patients with a “positive” or “negative” test result.

  • Product information on the emerging class of immunotherapeutics approved for use in veterinary medicine.

As one of the safest and most cost-effective means of infectious disease prevention, vaccination has long been a focal point of canine practice. This revision of the entire AAHA Canine Vaccination Guidelines is presented in an online format at aaha.org/CanineVaccinationGuidelines. Termed an “Online Educational Resource,” this iteration of the AAHA Canine Vaccination Guidelines offers readers immediate accessibility to current, “must-know” information that directly impacts clinical practice on a daily basis.

The table on vaccination recommendations in practice is an up-to-date, master reference that functions as a stand-alone resource covering all commercially available canine vaccines licensed in the United States and Canada. Core and noncore vaccines are listed along with recommendations for revaccination intervals and various precautions. The table contains links to sections in the Guidelines that provide additional, relevant detail. This is the only section available in print in JAAHA. The remainder of the sections listed below can be found at aaha.org/CanineVaccinationGuidelines.

Rabies vaccines are the only vaccines administered by veterinarians that are required by law. Because rabies laws may vary from state to state (or jurisdictions within states), a new section on rabies vaccination provides access to current state-by-state information on rabies and rabies vaccination law, and regulations that directly impact decisions veterinarians make in practice.

Another new section offers recommendations for dogs that are overdue for vaccination. Vaccine-specific guidance is provided for what is often an ambiguous aspect of veterinary practice, i.e., the canine patient that presents with an unknown or out-of-date vaccination history. Recommendations for core and noncore vaccines are presented.

Shelter-housed dogs represent a sizeable population of animals at increased risk of exposure to vaccine-preventable infectious diseases. The Guidelines include an updated table on recommendations for vaccination of shelter-housed dogs, including those in long-term housing facilities.

Another novel component of the Guidelines is a section on antibody testing (serology) as an adjunct to vaccination. Information is included that addresses not only the indications for testing, but also provides recommended actions based on whether the test results are “positive” or “negative.” Antibody testing represents a selective approach to assessing an individual dog’s response to vaccination. Determination of antibody status is especially relevant for the assessment of patients that have an unknown vaccination history, are overdue for vaccination, those undergoing chemotherapy, those receiving immunosuppressive drugs, as well as patients with a history of vaccine adverse reactions.

As noted in the section on legal considerations, veterinarians can exercise some professional discretion in deviating from vaccine label recommendations, such as determining appropriate revaccination intervals based the patient’s risk. On the other hand, the protocol for administering rabies vaccinations is not discretionary. Decisions surrounding the administration of rabies vaccines require strict adherence to statutory requirements.

The section on vaccine storage and handling summarizes “must know” information related to the storage and use of vaccines within the practice. Included are tips for avoiding misidentification of vaccines, monitoring storage conditions, and the consequences of subjecting vaccines to out-of-range temperatures. A link to comprehensive Center for Disease Control (CDC) guidelines for proper vaccine storage and handling of vaccines is provided.

Immunotherapeutic products represent a rapidly emerging class of biologics licensed for use in veterinary medicine. The Guidelines include a new section entitled therapeutic biologics specifically directed at informing veterinarians about the availability and intended use of these novel adjunctive immune-based therapies.

In the section on frequently asked questions, readers will find informative recommendations for dealing with an assortment of commonly encountered, vaccine-related situations seen in clinical practice.

The AAHA Canine Vaccination Guidelines support the implementation of effective, individualized pathways for the prevention of infectious diseases of dogs. Implicit in the Guidelines is the integral role vaccination plays in the veterinary profession’s emphasis on preventive healthcare and regular exams as the foundation of a long, active, and rewarding relationship between pets and their human companions. To read these guidelines in their entirety, visit aaha.org/CanineVaccinationGuidelines.

TABLE Vaccination Recommendations—Practice

          TABLE

NOTE: Vaccines designated as CORE should be administered to all dogs. However, because exposure risk to vaccine-preventable disease varies, selected NONCORE vaccines may be recommended as CORE in individual practices depending on geographic region, patient lifestyle, age, etc.

REFERENCES

The following citations apply to the “Vaccination Recommendations—Practice” table.

General Principles of Immunization

  • 1.
    Abdelmagid OY
    ,
    LarsonL
    ,
    PayneL
    , et al
    . Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges. Vet Ther2004;5(
    3
    ):17386.
  • 2.
    Chastant-Maillard S
    ,
    FreyburgerL
    ,
    MarcheteauE
    , et al
    . Timing of the intestinal barrier closure in puppies. Reprod Domest Anim2012;47(
    suppl 6
    ):190193.
  • 3.
    Davis-Wurzler GM
    . 2013 Update on current vaccination strategies in puppies and kittens. Vet Clin N Am Small Anim Pract2014;44(
    2
    ):23563.
  • 4.
    Day MJ
    ,
    SchultzRD
    . Vaccination. In: Veterinary Immunology: Principles and Practice.
    Boca Raton (FL)
    :
    Taylor and Francis
    ; 2014:224.
  • 5.
    Day MJ
    ,
    HorzinekMC
    ,
    SchultzRD
    , et al
    . Guidelines for the Vaccination of Dogs and Cats. World Small Animal Veterinary Association, Vaccine Guidelines Group. J Sm Anim Pract2016;57:E1E45.
  • 6.
    Ford RB
    . Companion animal vaccines. In:
    EttingerSJ
    ,
    FeldmanEC
    , eds. Textbook of Veterinary Internal Medicine. Vol 1.
    7th ed
    .
    St Louis
    :
    Elsevier Saunders
    ; 2010:853.
  • 7.
    Ford RB
    . Canine vaccination guidelines: Key points for veterinary practice. Today’s Vet Pract2012;2:206.
  • 8.
    Gill M
    ,
    SrinivasJ
    ,
    MorozovI
    , et al
    . Three-year duration of immunity for canine distemper, adenovirus, and parvovirus after vaccination with a multivalent canine vaccine. J Appl Res Vet Med2004;2(
    4
    ):22734.
  • 9.
    Greene CE
    ,
    SchultzRD
    . Immunoprophylaxis and immunotherapy. In:
    GreeneCE
    , ed. Infectious Diseases of the Dog and Cat.
    3rd ed
    .
    Philadelphia
    :
    WB Saunders
    ; 2006:1069119.
  • 10.
    Larson LJ
    ,
    SchultzRD
    . Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine. Vet Ther2007;8(
    4
    ):30510.
  • 11.
    Larson LJ
    ,
    NewburyS
    ,
    SchultzRD
    . Canine and feline vaccinations and immunology. In:
    MillerL
    ,
    HurleyKF,
    eds. Infectious Disease Management in Animal Shelters.
    Ames (IA)
    :
    Wiley-Blackwell
    ; 2009:6182.
  • 12.
    Mouzin DE
    ,
    LorenzenMJ
    ,
    HaworthJD
    , et al
    . Duration of serologic response to five viral antigens in dogs. J Am Vet Med Assoc2004;224(
    1
    ):5560.
  • 13.
    Renshaw RW
    ,
    ZylichNC
    ,
    LaverackMA
    , et al
    . Pneumovirus in dogs with acute respiratory disease. Emerg Infect Dis2010;16(
    6
    ):993995.
  • 14.
    Roth JA
    . Mechanistic bases for adverse vaccine reactions and vaccine failures. In:
    SchultzRD
    ,
    ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics.
    San Diego (CA)
    :
    Academic Press
    ; 1999:681700.
  • 15.
    Ruch-Gallie R
    ,
    MoroffS
    ,
    LappinMR
    . Adenovirus 2, Bordetella bronchiseptica, and Parainfluenza Molecular Diagnostic Assay Results in Puppies After vaccination with Modified Live Vaccines. J Vet Intern Med2016;30:1646.
  • 16.
    Schultz RD
    . Duration of immunity for canine and feline vaccines: a review. Vet Microbiol2006;117(
    1
    ):759.
  • 17.
    Schultz RD
    ,
    ThielB
    ,
    MukhtarE
    , et al
    . Age and long-term protective immunity in dogs and cats. J Comp Pathol2010;142(
    suppl 1
    ):S1028.
  • 18.
    Spickler AR
    ,
    RothJA
    . Adjuvants in veterinary vaccines: Modes of action and adverse effects. J Vet Intern Med2003;17(
    3
    ):27381.
  • 19.
    Tizard I
    . Vaccines and their production. In: Veterinary immunology.
    9th ed.
    St Louis
    :
    Elsevier-Saunders
    ; 2013:25870.
  • 20.
    Tizard I
    . The use of vaccines. In: Veterinary immunology.
    9th ed.
    St Louis
    :
    Elsevier-Saunders
    ; 2013:27282.

Pathogens

Canine Distemper Virus
  • 21.
    Jensen WA
    ,
    TottenJS
    ,
    LappinMR
    , et al
    . Use of serologic tests to predict resistance to Canine distemper virus-induced disease in vaccinated dogs. J Vet Diag Invest2015;27(
    5
    ):57680.
  • 22.
    Larson L
    ,
    SchultzRD
    . Effect of vaccination with rCDV vaccine immediately before exposure under shelter-like conditions. Vet Ther2006;7(
    2
    ):1138.
  • 23.
    Larson LJ
    ,
    SchultzRD
    . Three-year duration of immunity in dogs vaccinated with a canarypox-vectored recombinant canine distemper virus vaccine. Vet Ther2007;8(
    2
    ):1016.
  • 24.
    Pardo MC
    ,
    BaumanJE
    ,
    MackowiakM
    . Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am J Vet Res1997;58(
    8
    ):8336.
  • 25.
    Pardo MC
    ,
    TannerP
    ,
    BaumanJ
    , et al
    . Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus. J Comp Pathol2007;137(
    suppl 1
    ):S725.
  • 26.
    Perrone D
    ,
    BenderS
    ,
    NiewieskS
    . A comparison of the immune responses of dogs exposed to canine distemper virus (CDV) - Differences between vaccinated and wild-type virus exposed dogs. Can J Vet Res2010;74(
    3
    ):2147.
Canine Parvovirus
  • 27.
    Decaro N
    ,
    CrescenzoG
    ,
    DesarioC
    , et al
    . Long-term viremia and fecal shedding in pups after modified-live canine parvovirus vaccination. Vaccine2014;32:38503.
  • 28.
    Hernández-Blanco B
    ,
    Catala-LópezF
    . Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: A systematic review of controlled clinical trials. Vet Microbiol2015;180(
    1–2
    ):19.
  • 29.
    Larson LJ
    ,
    SchultzRD
    . Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?Vet Ther2008;9(
    2
    ):94101.
  • 30.
    Miranda C
    ,
    ThompsonG
    . Canine parvovirus in vaccinated dogs: a field study. Vet Rec2016;178(
    16
    ):397.
  • 31.
    Pratelli A
    ,
    CavalliA
    ,
    MartellaV
    , et al
    . Canine parvovirus (CPV) vaccination: comparison of neutralizing antibody responses in pups after inoculation with CPV2 or CPV2b modified live virus vaccine. Clin Diagn Lab Immunol2001;8(
    3
    ):6125.
  • 32.
    Ridel M
    ,
    TruyenU
    ,
    ReeseS
    , et al
    . Prevalence of antibodies to canine parvovirus and reaction to vaccination in client-owned, healthy dogs. Vet Rec2015;177:597.
  • 33.
    Spibey N
    ,
    GreenwoodNM
    ,
    SuttonD
    , et al
    . Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol2008;128(
    1–2
    ):4855.
  • 34.
    Wilson S
    ,
    IllambasJ
    ,
    SiedekE
    , et al
    . Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralizing antibody responses to CPV-2a and CPV-2c. Vaccine2014;32(
    42
    ):54204.
Canine Adenovirus (Canine Infectious Hepatitis)
  • 35.
    Greene CE
    . Infectious canine hepatitis and canine acidophil cell hepatitis. In:
    GreeneCE
    ,
    ed. Infectious Diseases of the Dog and Cat.
    4th ed
    .
    St. Louis
    :
    Elsevier-Saunders
    ; 2012:428.
Rabies
  • 36.
    Brown CM
    ,
    SlavinskiS
    ,
    EttestadP
    , et al
    . Compendium of Animal Rabies Prevention and Control, 2016. J Am Vet Med Assoc2016;248(
    5
    ):50517.
  • 37.
    Frana TS
    ,
    CloughNE
    ,
    GatewoodDM
    , et al
    . Postmarketing surveillance of rabies vaccines for dogs to evaluate safety and efficacy. J Am Vet Med Assoc2008;232(
    7
    ):10002.
  • 38.
    Monroe BP
    ,
    YagerP
    ,
    BlantonJ
    , et al
    . Rabies surveillance in the United States during 2014. J Am Vet Med Assoc2016;248(
    7
    ):77788.
  • 39.
    Moore MC
    ,
    DavisRD
    ,
    KangQ
    , et al
    . Comparison of anamnestic responses to rabies vaccination in dogs and cats with current and out-of-date vaccination status. J Am Vet Med Assoc2015;246(
    2
    ):20511.
  • 40.
    Murray KO
    ,
    HolmesKC
    ,
    HanlonCA
    . Rabies in vaccinated dogs and cats in the United States, 1997–2001. J Am Vet Med Assoc2009;235(
    6
    ):6915.
Leptospirosis
  • 41.
    Andre-Fontaine G
    . Diagnosis algorithm for leptospirosis in dogs: disease and vaccination effects on the serological results. Vet Rec2013;172(
    19
    ):502.
  • 42.
    Gautam R
    ,
    WuCC
    ,
    GuptillLF
    , et al
    . Detection of antibodies against Leptospira serovars via microscopic agglutination tests in dogs in the United States 2000-2007. J Am Vet Med Assoc2010;237(
    3
    ):2938.
  • 43.
    Goldstein R
    . Canine leptospirosis. Vet Clin N Am Small Anim Pract2010;40(
    6
    ):1091101.
  • 44.
    Ghneim GS
    ,
    ViersJH
    ,
    ChomelBB
    , et al
    . Use of a case-control study and geographic information systems to determine environmental and demographic risk factors for canine leptospirosis. Vet Res2007;38(
    1
    ):3750.
  • 45.
    Klaasen HL
    ,
    van der VeenM
    ,
    SuttonD
    , et al
    . A new tetravalent canine leptospirosis vaccine provides at least 12 months immunity against infection. Vet Immunol Immunopathol2014;158(
    1–2
    ):269.
  • 46.
    Langston CE
    ,
    Heuter KJ.Leptospirosis
    . A re-emerging zoonotic disease. Vet Clin North Am Small Anim Pract2003;33(
    4
    ):791807.
  • 47.
    Lee HS
    ,
    LevineM
    ,
    Guptill-YoranC
    , et al
    . Regional and temporal variations of Leptospira seropositivity in dogs in the United States, 2000-2010. J Vet Intern Med2014;28(
    3
    ):77988.
  • 48.
    Midence JN
    ,
    LeuteneggerCM
    ,
    ChandlerAM
    , et al
    . Effects of recent Leptospira vaccination on whole blood real-time PCR testing in healthy client-owned dogs. J Vet Intern Med2012;26(
    1
    ):14952.
  • 49.
    Moore GE
    . Leptospirosis: preventing a complex and elusive disease. Vet Rec2013;172(
    7
    ):17980.
  • 50.
    Raghavan RK
    ,
    BrennerKM
    ,
    HigginsJJ
    , et al
    . Neighborhood-level socioeconomic and urban land use risk factors of canine leptospirosis: 94 cases (2002-2009). Prev Vet Med2012;106(
    3–4
    ):32431.
  • 51.
    Raghavan RK
    ,
    BrennerKM
    ,
    HigginsJJ
    , et al
    . Evaluations of hydrologic risk factors for canine leptospirosis:94 cases (2002-2009). Prev Vet Med2012;107(
    1–2
    ):1059.
  • 52.
    Sykes JE
    ,
    HartmanK
    ,
    LunnKF
    , et al
    . 2010 ACVIM Small Animal Consensus Statement on Leptospirosis: Diagnosis, Epidemiology, Treatment, and Prevention. J Vet Intern Med2011;25(
    1
    ):113.
  • 53.
    Wilson S
    ,
    StirlingC
    ,
    ThomasA
    . A new multivalent (DHPPi/L4R) canine combination vaccine prevents infection, shedding and clinical signs following experimental challenge with four Leptospira serovars. Vaccine2013;31(
    31
    ):31314.
Borreliosis (Canine Lyme Disease)
  • 54.
    Conlon JA
    ,
    MatherTN
    ,
    TannerP
    , et al
    . Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi. Vet Ther2000;1(
    2
    ):96107.
  • 55.
    Ford RB
    ,
    EschnerA
    . Canine Lyme disease: how real the threat?Today’s Veterinary Practice2014;4(
    2
    ):704.
  • 56.
    Goldstein RE
    . Lyme disease. In:
    EttingerSJ
    ,
    FeldmanEC
    ,
    eds. Textbook of Veterinary Internal Medicine. Vol. 1.
    7th ed
    .
    St Louis
    :
    Elsevier Saunders
    ; 2010:868.
  • 57.
    Leschnik MW1
    ,
    KirtzG
    ,
    KhanakahG
    , et al
    . Humoral immune response in dogs naturally infected with Borrelia burgdorferi sensu lato and in dogs after immunization with a Borrelia vaccine. Clin Vaccine Immunol2010;17(
    5
    ):82835.
  • 58.
    Littman MP
    ,
    GoldsteinRE
    ,
    LabatoMA
    . ACVIM consensus statement on Lyme disease in dogs: diagnosis, treatment, and prevention. J Vet Intern Med2006;20(
    2
    ):42234.
  • 59.
    O'Connor TP
    ,
    EstyKJ
    ,
    HanscomJL
    , et al
    . Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein ofBorrelia burgdorferi. Clin Diagn Lab Immunol. 2004;11(
    3
    ):45862.
  • 60.
    Rhodes DV
    ,
    EarnhardtCG
    ,
    MatherTN
    , et al
    . Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation; implications for Lyme disease vaccine and diagnostic assay design. Vet J2013;198(
    2
    ):4128.
  • 61.
    Töpfer KH
    ,
    StraubingerRK
    . Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent: A study with five commercial vaccines using two different vaccination schedules. Vaccine2007;25(
    2
    ):31426.
Agents associated with Canine Infectious Respiratory Disease (CIRD)
  • 62.
    Anderson TC
    ,
    CrawfordPC
    ,
    DuboviEJ
    , et al
    . Prevalence of and exposure factors for seropositivity to H3N8 canine influenza virus in dogs with influenza-like illness in the United States. J Am Vet Med Assoc2013;242(
    2
    ):20916.
  • 63.
    Castleman WL
    ,
    PoweJR
    ,
    CrawfordPC
    , et al
    . Canine H3N8 influenza virus infection in dogs and mice. Vet Path2010;47(
    3
    ):50717.
  • 64.
    Davis R
    ,
    JayappaH
    ,
    AbdelmagidOY
    , et al
    . Comparison of the mucosal immune response in dogs vaccinated with either an intranasal avirulent live culture or a subcutaneous antigen extract vaccine ofBordetella bronchiseptica. Vet Ther2007;8(
    1
    ):3240.
  • 65.
    Deshpande MS
    ,
    JirjisFF
    ,
    TubbsAL
    , et al
    . Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther2009;10(
    3
    ):10312.
  • 66.
    Edinboro CH
    ,
    WardMP
    ,
    GlickmanLT
    . A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis (kennel cough) in dogs entering a humane shelter. Prev Vet Med2004;62(
    2
    ):8999.
  • 67.
    Ellis JA
    ,
    KrakowkaGS
    . A review of canine parainfluenza virus infection in dogs. J Am Vet Med Assoc2012;240:27384.
  • 68.
    Ellis J
    ,
    RhodesC
    ,
    LacosteS
    , et al
    . Antibody responses to Bordetella bronchiseptica in vaccinated and infected dogs. Can Vet J2014;55(
    9
    ):85764.
  • 69.
    Ellis JA
    . How well do vaccines for Bordetella bronchiseptica work in dogs? A critical review of the literature 1977-2014. Vet J2015;204(
    1
    ):516.
  • 70.
    Ellis JA
    ,
    GowSP
    ,
    WaldnerCL
    , et al
    . Comparative efficacy of intranasal and oral vaccines against Bordetella bronchiseptica in dogs. Vet J2016;212:717.
  • 71.
    Erles K
    ,
    BrownlieJ
    . Canine respiratory coronavirus: an emerging pathogen in the canine infectious respiratory disease complex. Vet Clin North Am Small Anim Pract2008;38(
    4
    ):81525.
  • 72.
    Ford RB
    . Bordetella bronchiseptica: beyond “kennel cough.” In:
    BonaguraJ
    ,
    TwedtDC
    ,
    eds. Kirk’s Current Veterinary Therapy XIV.
    St. Louis
    :
    Saunders-Elsevier
    ; 2009:64750.
  • 73.
    Gore T
    ,
    HeadleyM
    ,
    LarisR
    , et al
    . Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours. Vet Rec2005;156(
    15
    ):4823.
  • 74.
    Hess T
    ,
    ParkerD
    ,
    Hassal,
    et al
    . Evaluation of efficacy of oral administration of Bordetella bronchiseptica intranasal vaccine when used to protect puppies from tracheobronchitis due to Bordetella bronchiseptica infection. Intern J Appl Res Vet Med2011;9(
    3
    ):3005.
  • 75.
    Jacobs AA
    ,
    TheelenRP
    ,
    JaspersR
    , et al
    . Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. Vet Rec2005;157(
    1
    ):1923.
  • 76.
    Jacobs AA
    ,
    BergmanJG
    ,
    TheelenRP
    , et al
    . Compatibility of a bivalent modified-live vaccine against Bordetella bronchiseptica and CPiV, and a trivalent modified-live vaccine against CPV, CDV and CAV-2. Vet Rec2007;160(
    2
    ):415.
  • 77.
    Larson LJ
    ,
    HenningsonJ
    ,
    SharpP
    , et al
    . Efficacy of the canine influenza virus H3N8 vaccine to decrease severity of clinical disease after co-challenge with canine influenza virus and Streptococcus equi subsp. zooepidemicus. Clin Vaccine Immunol2011;18(
    4
    ):55964.
  • 78.
    Larson L
    ,
    ThielBE
    ,
    SharpP
    , et al
    . A comparative study of protective immunity provided by oral, intranasal and parenteral canine Bordetella bronchiseptica vaccines. Intern J Appl Res Vet Med2013;11(
    3
    ):15360.
  • 79.
    Lehar C
    ,
    JayappaH
    ,
    ErskineJ
    , et al
    . Demonstration of 1-year duration of immunity for attenuated Bordetella bronchiseptica vaccines in dogs. Vet Ther2008;9(
    4
    ):25762.
  • 80.
    Newbury S
    ,
    Godhardt-CooperJ
    ,
    PoulsenKP
    . Prolonged intermittent virus shedding during an outbreak of canine influenza A H3N2 virus infection in dogs in three Chicago area shelters: 16 cases (March to May 2015). J Am Vet Med Assoc2016;248(
    9
    ):10226.
  • 81.
    Payungporn S
    ,
    CrawfordPC
    ,
    KouoTS
    , et al
    . Influenza A virus (H3N8) in dogs with respiratory disease, Florida. Emerg Inf Dis2008;14(
    6
    ):9028.
  • 82.
    Squires RA
    . How well do vaccines against Bordetella bronchiseptica work in dogs?Vet J2015;204(
    3
    ):2378.
Crotalus Atrox (Western Diamondback Rattlesnake Vaccine)
  • 83.
    Wallis DM
    ,
    WallisJL
    . Rattlesnake vaccine to prevent envenomation toxicity in dogs. Presented at the Dr Ross O. Mosier 77th Annual Western Veterinary Conference. Las Vegas (NV), February 20–24, 2005.
  • 84.
    Cates CC
    ,
    ValoreEV
    ,
    CoutoMA
    , et al
    . Comparison of the protective effect of a commercially available western diamondback rattlesnake toxoid vaccine for dogs against envenomation of mice with western diamondback rattlesnake (Crotalus atrox), northern Pacific rattlesnake (Crotalus oreganus oreganus), and southern Pacific rattlesnake (Crotalus oreganus helleri) venom. Am J Vet Res2015;76(
    3
    ):2729.
Canine Enteric Coronavirus
  • 85.
    Greene CE
    ,
    DecaroN
    . Canine viral enteritis. In:
    GreeneCR
    ,
    ed. Infectious Diseases of the Dog and Cat.
    4th ed
    .
    St. Louis
    :
    Elsevier-Saunders
    ; 2012:6780.
Copyright: © 2017 by American Animal Hospital Association 2017

Contributor Notes

Correspondence: linktpa@aol.com (L.V.W.)

CONTRIBUTING REVIEWERS

Catherine M. Brown, DVM, MSc, MPH (Massachusetts Department of Public Health); Anthony E. Cascino, Jr. Attorney at Law (Cascino & Assoc, P.C.; Chicago, Illinois); Leah A. Cohn, DVM, PhD, DACVIM (University of Missouri); Cynda Crawford, DVM, PhD (Maddie’s Shelter Program, University of Florida); Michael J. Day, BSc, BVMS (Hons), PhD, DECVP (University of Bristol, United Kingdom); Cynthia Delany, DVM (University of California, Davis); Brian DiGangi, DVM, DABVP (University of Florida); Kelli Ferris, DVM (North Carolina State University); Laurel Gershwin, DVM, PhD, DACVM (University of California, Davis); Douglas C. Jack, Solicitor (Borden Ladner Gervais LLP, Toronto, Canada); Linda Janowitz, DVM (Peninsula Humane Society); Lila Miller, DVM (American Society for the Prevention of Cruelty to Animals, New York City); Susan Moore, MS, PhD, director of KSVDL Rabies Laboratory (Kansas State University); Kris Otteman, DVM (Oregon Humane Society); Apryl Steele, DVM (Chief Operating Officer, Dumb Friends League); Brenda Stevens, DVM (North Carolina State University); Amy Stone, DVM, PhD (University of Florida); Jane Sykes, BVSc, PhD, DACVIM (University of California, Davis)

* These guidelines were prepared by a task force of experts convened by the American Animal Hospital Association. This document is intended as a guideline only, not an AAHA standard of care. These guidelines and recommendations should not be construed as dictating an exclusive protocol, course of treatment, or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to each individual practice setting. Evidence-based support for specific recommendations has been cited whenever possible and appropriate. Other recommendations are based on practical clinical experience and a consensus of expert opinion. Further research is needed to document some of these recommendations. Because each case is different, veterinarians must base their decisions on the best available scientific evidence in conjunction with their own knowledge and experience.

These guidelines were sponsored by a generous educational grant from Boehringer Ingelheim, Merial, Merck Animal Health, and Zoetis. They were subjected to a formal peer-review process.

The AAHA Canine Vaccination Guidelines Task Force gratefully acknowledges the contribution of Mark Dana of Scientific Communications Services, LLC, in the preparation of the Executive Summary.

R.B. Ford was the lead editor of the AAHA Canine Vaccination Guidelines Task Force.

L.V. Welborn was the chair of the AAHA Canine Vaccination Guidelines Task Force.

  • Download PDF